Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T19:38:22.848Z.
Calculation as of: 2026-10-06T19:38:22.848Z.
Quote observation: 2026-10-06T19:35:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69c6abe1898d62982c9f5472fcc208679ef9964d1dbc89e7ebe68f1e3eabf120
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Protara Therapeutics, Inc.
Market Cap
$145.33M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$145.70M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$145.96M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$145.68M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$144.06M
Free Cash Flow Yield
87.35%
TTM Avg
20.53%
3Y Avg
20.53%
5Y Avg
20.53%
Market Cap
$146.62M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$146.67M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$147.13M
Free Cash Flow Yield
N/A
TTM Avg
18.33%
3Y Avg
11.51%
5Y Avg
10.85%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | $145.33M | N/A | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $145.70M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $145.96M | N/A | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $145.68M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $144.06M | 87.35% | 20.53% | 20.53% | 20.53% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $146.67M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $146.82M | N/A | 2.70% | 2.70% | 2.70% |
| Voyager Therapeutics, Inc. (VYGR)vs › | $147.13M | N/A | 18.33% | 11.51% | 10.85% |
| Nyxoah S.A. (NYXH)vs › | $142.60M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
